Načítá se...
Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma
The MEK inhibitor MEK162 is the first targeted therapy agent with clinical activity in patients whose melanomas harbor NRAS mutations; however, median PFS is 3.7 months, suggesting the rapid onset of resistance in the majority of patients. Here we show that treatment of NRAS-mutant melanoma cell lin...
Uloženo v:
| Hlavní autoři: | , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4211982/ https://ncbi.nlm.nih.gov/pubmed/25130256 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pcmr.12303 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|